SG11201407703QA - Methanethione compounds having antiviral activity - Google Patents

Methanethione compounds having antiviral activity

Info

Publication number
SG11201407703QA
SG11201407703QA SG11201407703QA SG11201407703QA SG11201407703QA SG 11201407703Q A SG11201407703Q A SG 11201407703QA SG 11201407703Q A SG11201407703Q A SG 11201407703QA SG 11201407703Q A SG11201407703Q A SG 11201407703QA SG 11201407703Q A SG11201407703Q A SG 11201407703QA
Authority
SG
Singapore
Prior art keywords
international
compound
formula
stockholm
methanethione
Prior art date
Application number
SG11201407703QA
Other languages
English (en)
Inventor
Mohammed Homman
Ngarita Kingi
Jan Bergman
Robert Berg
Original Assignee
Vironova Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48444409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201407703Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vironova Ab filed Critical Vironova Ab
Publication of SG11201407703QA publication Critical patent/SG11201407703QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201407703QA 2012-05-18 2013-05-17 Methanethione compounds having antiviral activity SG11201407703QA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261648700P 2012-05-18 2012-05-18
US201261659516P 2012-06-14 2012-06-14
US201261666286P 2012-06-29 2012-06-29
US201361774991P 2013-03-08 2013-03-08
PCT/EP2013/060266 WO2013171334A1 (en) 2012-05-18 2013-05-17 Methanethione compounds having antiviral activity

Publications (1)

Publication Number Publication Date
SG11201407703QA true SG11201407703QA (en) 2015-01-29

Family

ID=48444409

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407703QA SG11201407703QA (en) 2012-05-18 2013-05-17 Methanethione compounds having antiviral activity

Country Status (21)

Country Link
US (1) US9359310B2 (ja)
EP (1) EP2870141B1 (ja)
JP (2) JP6484168B2 (ja)
KR (1) KR102092207B1 (ja)
CN (1) CN104540810B (ja)
AU (1) AU2013261735B2 (ja)
BR (1) BR112014028632B1 (ja)
CA (1) CA2879816C (ja)
CL (1) CL2014003116A1 (ja)
DK (1) DK2870141T3 (ja)
EA (1) EA029044B1 (ja)
ES (1) ES2657942T3 (ja)
HK (1) HK1210165A1 (ja)
IL (1) IL235742A0 (ja)
IN (1) IN2014DN10658A (ja)
MX (1) MX356846B (ja)
MY (1) MY169094A (ja)
NZ (1) NZ702073A (ja)
SG (1) SG11201407703QA (ja)
WO (1) WO2013171334A1 (ja)
ZA (1) ZA201409220B (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014028632B1 (pt) * 2012-05-18 2020-01-28 Vironova Ab composto, composição farmacêutica, e, método para preparar um composto
CN107056762B (zh) * 2016-12-22 2020-08-28 四川百利药业有限责任公司 一种用作抗流感病毒的双羰基类似物
WO2021204924A1 (en) 2020-04-09 2021-10-14 Vironova Medical Ab Compounds for use in the treatment of hypercytokinemia
WO2021204923A1 (en) 2020-04-09 2021-10-14 Vironova Medical Ab Antiviral agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642390B2 (en) 2001-07-11 2003-11-04 Lexicon Pharmaceuticals, Inc. One step synthesis of 1,2,3-triazole carboxylic acids
EP1590329A1 (fr) * 2003-01-28 2005-11-02 Aventis Pharma S.A. Produits n-aryl-heteroaromatiques, compositions les contenant et utilisation
US8207205B2 (en) 2008-04-21 2012-06-26 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
CN102596946B (zh) 2009-08-05 2015-06-17 港大科桥有限公司 抗病毒化合物及其制备和使用方法
ES2564257T3 (es) * 2010-09-28 2016-03-21 Bristol-Myers Squibb Company Nuevos análogos de piperazina con grupos heteroarilo sustituidos como antivirales de amplio espectro de la gripe
EP2484655A1 (en) 2011-02-04 2012-08-08 Vironova AB A thionation process and a thionating agent
BR112014028632B1 (pt) * 2012-05-18 2020-01-28 Vironova Ab composto, composição farmacêutica, e, método para preparar um composto
JP6762767B2 (ja) * 2016-06-01 2020-09-30 キヤノン株式会社 撮像素子、撮像装置、および撮像信号処理方法

Also Published As

Publication number Publication date
HK1210165A1 (en) 2016-04-15
IL235742A0 (en) 2015-02-01
EP2870141A1 (en) 2015-05-13
JP2018065817A (ja) 2018-04-26
AU2013261735A1 (en) 2015-01-22
ES2657942T3 (es) 2018-03-07
MX2014014007A (es) 2015-05-11
AU2013261735B2 (en) 2017-07-20
CN104540810A (zh) 2015-04-22
BR112014028632A2 (pt) 2017-06-27
BR112014028632B1 (pt) 2020-01-28
NZ702073A (en) 2017-07-28
MY169094A (en) 2019-02-18
EA029044B1 (ru) 2018-02-28
ZA201409220B (en) 2016-08-31
CA2879816A1 (en) 2013-11-21
CN104540810B (zh) 2017-01-18
DK2870141T3 (da) 2018-01-29
WO2013171334A1 (en) 2013-11-21
US20150133468A1 (en) 2015-05-14
US9359310B2 (en) 2016-06-07
KR102092207B1 (ko) 2020-03-23
BR112014028632A8 (pt) 2018-04-03
EA201401277A1 (ru) 2015-04-30
MX356846B (es) 2018-06-18
CL2014003116A1 (es) 2015-08-07
JP6484168B2 (ja) 2019-03-13
KR20150012289A (ko) 2015-02-03
EP2870141B1 (en) 2017-11-22
JP2015517516A (ja) 2015-06-22
CA2879816C (en) 2020-07-07
IN2014DN10658A (ja) 2015-08-28

Similar Documents

Publication Publication Date Title
SG11201407228PA (en) N-aryltriazole compounds as lpar antagonists
SG11201407037UA (en) Catechol o-methyltransferase activity inhibiting compounds
SG11201407534PA (en) New diazaspirocycloalkane and azaspirocycloalkane
SG11201408094YA (en) Neprilysin inhibitors
SG11201407220YA (en) N-alkyltriazole compounds as lpar antagonists
SG11201407200TA (en) Liquid formulation
SG11201408251SA (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
SG11201408659UA (en) Load carrying platform shuttle
SG11201907650RA (en) Personal therapy and exercise monitoring and oversight devices, systems, and related methods
SG11201408303WA (en) Adhesive compositions of propylene-based and ethylene-based polymers
SG11201408539UA (en) Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof
SG11201408237YA (en) Compound as wnt signaling inhibitor, composition, and use thereof
SG11201908640TA (en) Pyrrolidinones and a process to prepare them
SG11201408641UA (en) Phenoxyethyl piperidine compounds
SG11201408629QA (en) Dimethyl-benzoic acid compounds
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201407546QA (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
SG11201407189XA (en) C-17 bicyclic amines of triterpenoids with hiv maturation inhibitory activity
SG11201407536UA (en) Topical pharmaceutical compositions comprising terbinafine and urea
SG11201407229UA (en) Substituted pyrazole compounds as lpar antagonists
SG11201407345QA (en) Pyrazole compounds as sglt1 inhibitors
SG11201406787TA (en) Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies
SG11201806393QA (en) Use of gabaa receptor modulators for treatment of itch
SG11201901438VA (en) Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
SG11201407575PA (en) 5-amino[1,4]thiazines as bace 1 inhibitors